

## RENAL DISEASE TREATMENTS: PRODUCTS AND THERAPIES



HLC073B  
June 2016

Cheng-Yuk Lee  
*Project Analyst*

ISBN: 1-62296-307-5



**BCC Research**  
49 Walnut Park, Building 2  
Wellesley, MA 02481 USA  
866-285-7215 (toll-free within the USA),  
or (+1) 781-489-7301  
[www.bccresearch.com](http://www.bccresearch.com)  
[information@bccresearch.com](mailto:information@bccresearch.com)

**TABLE OF CONTENTS**

<b>TOPIC</b>	<b>PAGE NO.</b>
CHAPTER 1 INTRODUCTION	2
STUDY GOALS AND OBJECTIVES	2
REASONS FOR DOING THE STUDY	2
SCOPE OF REPORT	3
INTENDED AUDIENCE	4
METHODOLOGY AND INFORMATION SOURCES	4
ANALYST'S CREDENTIALS	5
RELATED BCC RESEARCH REPORTS	5
BCC RESEARCH WEBSITE	5
DISCLAIMER	5
CHAPTER 2 SUMMARY	7
<i>SUMMARY TABLE THE U.S. MARKET FOR KIDNEY DISEASE TREATMENT, THROUGH 2021 (\$ MILLIONS)</i>	7
<i>SUMMARY FIGURE THE U.S. MARKET FOR KIDNEY DISEASE TREATMENT, 2015-2021 (\$ MILLIONS)</i>	7
CHAPTER 3 KIDNEY DISEASE OVERVIEW	9
KIDNEY FUNCTION	9
RENAL DISEASE	11
SYMPTOMS	11
CLASSIFICATION OF KIDNEY INJURY AND DISEASE	12
<i>TABLE 1 CRITERIA FOR KIDNEY INJURY/DISEASE</i>	13
GLOMERULAR FILTRATION RATE (GFR)	13
LIMITATION OF CREATININE IN GFR MEASUREMENT	16
DECREASED ESTIMATED GFR	18
<i>TABLE 2 STAGES OF CHRONIC KIDNEY DISEASE</i>	18
RELATIONSHIP BETWEEN ACUTE KIDNEY INJURY AND CHRONIC KIDNEY DISEASE	19
<i>FIGURE 1 RENAL STATUS ONE YEAR FOLLOWING DISCHARGE FROM AKI HOSPITALIZATION AMONG MEDICARE PATIENTS AGED 66+, 2010-2011 (% OF PATIENTS WITHOUT CKD BEFORE AKI)</i>	19
<i>FIGURE 2 POTENTIAL OUTCOME OF ACUTE KIDNEY INJURY</i>	20
CONNECTION BETWEEN CARDIOVASCULAR AND RENAL DISEASE	21
<i>FIGURE 3 CARDIOVASCULAR DISEASE IN PATIENTS WITH OR WITHOUT CKD, 2012 (%)</i>	22
EPIDEMIOLOGY	23
HOSPITALIZATION FROM KIDNEY DISEASE	25
<i>FIGURE 4 TRENDS OF KIDNEY DISEASE INCIDENT RATE IN THE U.S.,1980-2005</i>	26
THE ECONOMIC BURDEN AND COVERAGE OF KIDNEY DISEASE	26
MEDICARE'S ESRD PROGRAM	27
CHAPTER 4 ACUTE KIDNEY DISEASE OVERVIEW	30
<i>FIGURE 5 CLASSIFICATION OF ACUTE KIDNEY INJURY</i>	30
PRERENAL CAUSES	31
<i>TABLE 3 COMMON MEDICATIONS THAT CAUSE ACUTE KIDNEY INJURY</i>	31
INTRINSIC RENAL CAUSES	33

<b>TOPIC</b>	<b>PAGE NO.</b>
POSTRENAL CAUSES	34
EPIDEMIOLOGY	34
<i>TABLE 4 RIFLE AND AKIN CRITERIA FOR DIAGNOSIS AND CLASSIFICATION OF AKI</i>	34
DIAGNOSIS	35
<i>FIGURE 6 TREATMENT FLOWCHART FOR ACUTE KIDNEY INJURY</i>	35
NOVEL AKI BIOMARKER	36
HOSPITALIZATION IN PATIENTS WITH ACUTE KIDNEY DISEASE	37
<i>FIGURE 7 NUMBER OF HOSPITALIZATIONS WITH ACUTE KIDNEY INJURY, 1979-2002</i>	37
<i>TABLE 5 CHARACTERISTICS OF MEDICARE PATIENTS AGED 66 AND ABOVE WITH AT LEAST ONE AKI HOSPITALIZATION: AGE, SEX, RACE, CKD, DM, BY YEAR, 2003-2012</i>	39
AKI PREVALENCE	40
<i>TABLE 6 NUMBER OF PATIENTS WITH AKI IN THE UNITED STATES BY AREA, THROUGH 2021</i>	40
CHAPTER 5 TREATMENT FOR ACUTE KIDNEY DISEASE	42
PHARMACEUTICALS USED IN ACUTE KIDNEY INJURY	43
FUROSEMIDE	43
DOPAMINE	43
EPINEPHRINE	44
NOVEL PHARMACEUTICALS IN DEVELOPMENT	45
ACUTE RENAL REPLACEMENT THERAPY	45
INTERMITTENT HEMODIALYSIS	45
CONTINUOUS RENAL REPLACEMENT THERAPY	46
<i>FIGURE 8 SCHEMATIC OF CONTINUOUS RENAL REPLACEMENT THERAPY</i>	46
<i>FIGURE 9 SCHEMATIC OF DIFFERENT TYPES OF CRRT</i>	48
SUSTAINED LOW EFFICIENCY DIALYSIS	48
COMPARISON OF THE RENAL REPLACEMENT THERAPY	48
<i>TABLE 7 CHARACTERISTICS OF DIALYSIS OPTIONS FOR TREATING AKI</i>	49
INITIATION OF RENAL REPLACEMENT THERAPY	49
COST OF RRT	50
ECONOMICS OF AKI	51
<i>TABLE 8 BREAKDOWN OF AVERAGE AKI TREATMENT COSTS BY SUBCATEGORY OF CARE (\$)</i>	51
THE U.S. MARKET FOR TREATING AKI	52
<i>TABLE 9 U.S. MARKET FOR ACUTE KIDNEY INJURY TREATMENT, THROUGH 2021 (\$ MILLIONS)</i>	52
PHARMACEUTICALS IN AKI TREATMENT	52
RRT IN AKI TREATMENT	53
CHAPTER 6 CHRONIC KIDNEY DISEASE	55
OVERVIEW	55
EPIDEMIOLOGY OF RENAL DISEASE	55
<i>TABLE 10 STAGES OF CHRONIC KIDNEY DISEASE: A CLINICAL ACTION PLAN</i>	56
<i>TABLE 11 AWARENESS, TREATMENT AND MEASURES OF CONTROL OF RISK FACTORS, 1998-2012 (% OF NHANES PARTICIPANTS)</i>	57
CAUSE OF CHRONIC KIDNEY DISEASE	57
<i>TABLE 12 CLASSIFICATION OF CHRONIC KIDNEY DISEASE BY PATHOLOGY, ETIOLOGY AND PREVALENCE IN PATIENTS WITH ESRD</i>	58

<b>TOPIC</b>	<b>PAGE NO.</b>
MEDICATION CAUSES CHRONIC KIDNEY DISEASE AND RELATED COMPLICATIONS	60
<i>TABLE 13 COMMON MEDICATION ASSOCIATED WITH CHRONIC KIDNEY DISEASE</i>	61
ANEMIA	61
<i>FIGURE 10 SCHEMATIC REPRESENTATION OF THE MECHANISMS UNDERLYING ANEMIA OF CKD</i>	63
DIABETIC NEPHROPATHY	64
<i>FIGURE 11 RECOGNIZED MOLECULAR MECHANISMS INVOLVED IN PATHOGENESIS OF DIABETIC KIDNEY DISEASE</i>	65
ELECTROLYTE ABNORMALITY	66
Potassium Homeostasis	66
Hyperphosphatemia	66
<i>FIGURE 12 MECHANISMS OF PHOSPHATE HOMEOSTASIS</i>	67
HYPERTENSION	67
NUMBER OF INDIVIDUALS WITH CKD	68
<i>FIGURE 13 CKD PATIENTS AWARE OF THEIR KIDNEY DISEASE, 2001-2012</i>	69
<i>TABLE 14 PATIENTS WITH CKD AND AWARENESS BY STAGE, 2012 (NUMBER AND %)</i>	69
<i>FIGURE 14 PREVALENCE OF CKD BY STAGE AMONG NHANES PARTICIPANTS, 1988-2012</i>	70
<i>FIGURE 15 TRENDS IN NUMBER OF PREVALENT ESRD CASES IN THE U.S. POPULATION BY AGE GROUP, 1996-2013 (THOUSANDS)</i>	70
<i>TABLE 15 NUMBER AND PERCENTAGE OF INCIDENT CASES OF HEMODIALYSIS (HD), PERITONEAL DIALYSIS (PD) AND TRANSPLANTATION IN THE U.S. POPULATION BY AGE, SEX, RACE, ETHNICITY AND PRIMARY CAUSE OF ESRD, 2013</i>	72
<i>TABLE 16 PREVALENCE OF CKD IN NHANES POPULATION WITHIN AGE, SEX, RACE/ETHNICITY AND RISK-FACTOR CATEGORIES, 1998-2012 (%)</i>	73
HOSPITALIZATION AND MORTALITY IN PATIENTS WITH CHRONIC KIDNEY DISEASE	73
<i>TABLE 17 UNADJUSTED AND ADJUSTED ALL-CAUSE HOSPITALIZATION RATES FOR MEDICARE PATIENTS AGED 66 AND OLDER BY CKD STATUS, 2012</i>	74
<i>FIGURE 16 ADJUSTED ALL-CAUSE HOSPITALIZATION RATES FOR MEDICARE PATIENTS AGED 66 AND OLDER BY CKD STATUS AND STAGE, 2012 (NO. OF ADMISSIONS)</i>	74
<i>FIGURE 17 ADJUSTED ALL-CAUSE HOSPITALIZATION RATES IN MEDICARE PATIENTS AGED 66 AND OLDER, BY RACE, CKD STATUS AND STAGE, 2012</i>	75
<i>FIGURE 18 UNADJUSTED AND ADJUSTED ALL-CAUSE MORTALITY RATE FOR MEDICARE PATIENTS</i>	76
CKD TRENDS IN THE WORLD	77
<i>TABLE 18 INCIDENCE OF ESRD BY COUNTRY, 2013 (PER MILLION POPULATION)</i>	77
<i>TABLE 19 PREVALENCE OF ESRD BY COUNTRY, 2013 (NO./%)</i>	79
<i>TABLE 20 TOP TEN COUNTRIES HAVING THE HIGHEST % RISE IN ESRD INCIDENCE RATE PLUS THE U.S., 2001 AND 2013</i>	80
<i>TABLE 21 FIVE COUNTRIES HAVING THE LARGEST % DECLINE IN ESRD INCIDENCE RATE, 2001 AND 2013</i>	80
<i>TABLE 22 PERCENTAGE OF INCIDENT ESRD PATIENTS DUE TO DIABETES BY COUNTRY, 2013 (%)</i>	81
COSTS OF CHRONIC KIDNEY DISEASE	82
CHAPTER 7 PHARMACEUTICAL THERAPY STRATEGY AND MARKET FOR CHRONIC KIDNEY DISEASE	84
DRUG PRESCRIBING IN CHRONIC KIDNEY DISEASE	84

<b>TOPIC</b>	<b>PAGE NO.</b>
PHARMACEUTICAL THERAPIES	85
<i>TABLE 23 PREVALENCE OF HYPERTENSION AND DYSLIPIDEMIA BY CKD STAGE (%)</i>	85
<i>TABLE 24 THE COMMONLY PRESCRIBED CLASS OF MEDICATION IN CHRONIC KIDNEY DISEASE PATIENTS (%)</i>	86
ANTIHYPERTENSIVES	86
<i>TABLE 25 RECOMMENDED ANTIHYPERTENSIVE AGENTS FOR PATIENTS WITH CHRONIC KIDNEY DISEASE AND HYPERTENSION</i>	87
ACE INHIBITORS	87
<i>TABLE 26 COMMONLY PRESCRIBED ACE INHIBITORS: BRAND NAME, GENERIC NAME AND MANUFACTURER</i>	88
ANGIOTENSIN RECEPTOR BLOCKERS	88
<i>TABLE 27 COMMONLY PRESCRIBED ANGIOTENSIN RECEPTOR BLOCKERS: BRAND NAME, GENERIC NAME AND MANUFACTURER</i>	88
BETA BLOCKERS	89
<i>TABLE 28 COMMONLY PRESCRIBED BETA BLOCKERS: BRAND NAME, GENERIC NAME AND MANUFACTURER</i>	89
CALCIUM CHANNEL BLOCKERS	90
<i>TABLE 29 COMMONLY PRESCRIBED CALCIUM CHANNEL BLOCKERS: BRAND NAME, GENERIC NAME AND MANUFACTURER</i>	90
DIRECT RENIN INHIBITORS	91
ANTHYPERKALEMIA	91
NOVEL DEVELOPMENT FOR TREATING HYPERKALEMIA	91
Patiromer	92
Sodium Zirconium Cyclosilicate	92
<i>TABLE 30 LIST OF ANTIHYPERKALEMIA MEDICATION IN DEVELOPMENT: BRAND NAME, GENERIC NAME, MANUFACTURER AND CLINICAL STAGE</i>	93
ANTHYPERPHOSPHATEMIA	93
<i>TABLE 31 COMMONLY PRESCRIBED PHOSPHATE BINDER: BRAND NAME, GENERIC NAME AND MANUFACTURER</i>	94
CHOLESTEROL MANAGEMENT MEDICATIONS	95
STATINS	95
<i>TABLE 32 COMMONLY PRESCRIBED STATIN: BRAND NAME, GENERIC NAME AND MANUFACTURER</i>	95
BILE ACID SEQUESTRANTS	96
<i>TABLE 33 COMMONLY PRESCRIBED BILE ACID SEQUESTRANTS: BRAND NAME, GENERIC NAME AND MANUFACTURER</i>	96
CHOLESTEROL ABSORPTION INHIBITORS	96
FIBRATES	96
<i>TABLE 34 COMMONLY PRESCRIBED FIBRATES: BRAND NAME, GENERIC NAME AND MANUFACTURER</i>	97
NIACIN	97
COMBINATION MEDICATIONS	97
DIURETICS	97
THIAZIDE DIURETICS	98
LOOP DIURETICS	98
POTASSIUM-SPARING DIURETICS	98
<i>TABLE 35 COMMONLY PRESCRIBED DIURETICS: BRAND NAME, GENERIC NAME AND MANUFACTURER</i>	99
ERYTHROPOIESIS-STIMULATING AGENTS	100

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 36 COMMONLY PRESCRIBED ERYTHROPOIESIS-STIMULATING AGENTS: BRAND NAME, GENERIC NAME AND MANUFACTURER</i>	100
BIOSIMILAR DEVELOPMENT IN EPOGEN	101
SAFETY CONCERN FROM USING ERYTHROPOIESIS-STIMULATING AGENTS	102
NOVEL THERAPEUTIC DEVELOPMENT FOR RED BLOOD CELL STIMULATION	103
Hypoxia Inducible Factor-Prolyl Hydroxylase Inhibitors	103
<i>TABLE 37 LIST OF HIF-PH INHIBITORS IN THE DEVELOPMENT: MANUFACTURER AND RESPECTIVE CLINICAL STAGE</i>	103
Gene Therapy	104
IRON THERAPY	104
<i>TABLE 38 COMMONLY PRESCRIBED IRON SUPPLEMENT: BRAND NAME, GENERIC NAME AND MANUFACTURER</i>	105
GLUCOSE MANAGEMENT	105
<i>TABLE 39 COMMONLY PRESCRIBED GLUCOSE MANAGEMENT: BRAND NAME, GENERIC NAME AND MANUFACTURER</i>	106
<i>TABLE 40 LIST OF NOVEL AGENT FOR TREATING DIABETIC NEPHROPATHY: MANUFACTURER AND RESPECTIVE CLINICAL STAGE</i>	108
OTHER	108
<i>TABLE 41 COMMONLY PRESCRIBED MEDICATION FOR CHRONIC KIDNEY DISEASE: BRAND NAME, GENERIC NAME AND MANUFACTURER</i>	109
HORMONES	109
ACTIVE VITAMIN D	109
CALCIUM-LOWERING DRUGS	110
ADDITIONAL MEDICATIONS FOR DIALYSIS PATIENTS	110
Heparin	110
Citrate Anticoagulant	111
MEDICATIONS FOR CKD PATIENTS ON PERITONEAL DIALYSIS	111
INTRAPERITONEAL DOSING OF MEDICATIONS	111
DRUGS USED IN CONJUNCTION WITH KIDNEY TRANSPLANTATION	112
INDUCTION DRUGS	112
IMMUNOSUPPRESSANT AGENTS FOR KIDNEY TRANSPLANT	112
<i>FIGURE 19 IMMUNOSUPPRESSION USE IN PEDIATRIC KIDNEY TRANSPLANT RECIPIENTS</i>	115
<i>TABLE 42 COMMONLY PRESCRIBED IMMUNOSUPPRESSANT DRUGS: BRAND NAME, GENERIC NAME AND MANUFACTURER</i>	115
<i>TABLE 43 IMMUNOSUPPRESSION MAINTENANCE REGIMEN AT DISCHARGE AND 1 YEAR AFTER TRANSPLANT, 2006</i>	116
<i>TABLE 44 IMMUNOSUPPRESSION DRUG USE, INDUCTION DRUGS, AT DISCHARGE, AT ONE YEAR POSTTRANSPLANT, 2005 AND 2006 (%)</i>	117
BARRIERS TO ADHERENCE IN CHRONIC KIDNEY DISEASE	118
<i>TABLE 45 FACTOR LINKED WITH NONCOMPLIANCE IN CHRONIC DISEASE</i>	118
COSTS	118
<i>TABLE 46 COSTS OF COMMONLY USED PRESCRIPTION DRUGS FOR TREATING RENAL FAILURE AND ASSOCIATED DISEASES</i>	119
MARKET ANALYSIS OF PHARMACEUTICAL THERAPY FOR CHRONIC KIDNEY DISEASE	120
<i>TABLE 47 THE U.S. MARKET FOR PHARMACEUTICALS USED IN CHRONIC KIDNEY DISEASE TREATMENT BY TYPE, THROUGH 2021 (\$ MILLIONS)</i>	121
THE MARKET FOR PHARMACEUTICALS USED IN CHRONIC KIDNEY DISEASE MANAGEMENT	121

<b>TOPIC</b>	<b>PAGE NO.</b>
THE MARKET FOR PHARMACEUTICALS USED IN KIDNEY DIALYSIS	121
<i>TABLE 48 COMMON DRUG CLASSES USED BY PART D-ENROLLED DIALYSIS PATIENTS, BY PERCENTAGE OF PATIENTS, DRUG CLASS, 2013 (%)</i>	122
<i>TABLE 49 COMPARISON OF 2008 AND 2012-BASED ESRD MARKET BASKET COST CATEGORIES AND WEIGHTS</i>	123
THE MARKET FOR PHARMACEUTICALS USED IN KIDNEY TRANSPLANTATION	124
COMPREHENSIVE IMMUNOSUPPRESSIVE DRUG COVERAGE FOR KIDNEY TRANSPLANT PATIENTS ACT OF 2013	124
CHAPTER 8 MARKET OF RENAL REPLACEMENT PRODUCTS AND SURGICAL PROCEDURES FOR END STAGE RENAL DISEASE	126
DIALYSIS OVERVIEW	126
<i>FIGURE 20 MECHANISMS OF SOLUTE REMOVAL IN DIALYSIS</i>	126
<i>FIGURE 21 TRENDS IN THE NUMBER OF INCIDENT CASES OF ESRD IN THE U.S. POPULATION BY MODALITY, 1980-2012 (THOUSANDS)</i>	127
<i>TABLE 50 MARKET SHARE OF OVERALL DIALYSIS PRODUCTS, 2014 (%)</i>	128
HEMODIALYSIS	129
<i>FIGURE 22 SCHEMATIC OF THE HEMODIALYSIS MEMBRANE</i>	129
MODES OF HEMODIALYSIS	130
Hemofiltration	130
Hemodiafiltration	131
HEMODIALYSIS SYSTEM	131
<i>FIGURE 23 SCHEMATIC OF TYPICAL HEMODIALYSIS SYSTEM</i>	131
MEASURING DIALYZER PERFORMANCE	132
DIALYZER REUSE	132
DIALYSATE	133
Sodium Citrate-Containing Dialysate	134
<i>TABLE 51 DIALYSATE PRODUCTS FOR HD, PD AND CRRT</i>	134
HOME HEMODIALYSIS	135
Novel Development in Home Hemodialysis Systems	136
PERITONEAL DIALYSIS	136
MODES OF PERITONEAL DIALYSIS	137
Continuous Ambulatory Peritoneal Dialysis	137
<i>FIGURE 24 CONTINUOUS AMBULATORY PERITONEAL DIALYSIS</i>	138
Continuous Cycler-Assisted Peritoneal Dialysis	138
Nocturnal Intermittent Peritoneal Dialysis	139
Tidal Peritoneal Dialysis	139
Dialysate for PD	139
PERITONEAL DIALYSIS EQUIPMENT MANUFACTURERS	140
<i>TABLE 52 PERITONEAL DIALYSIS SYSTEMS, TYPE AND MANUFACTURER</i>	140
<i>TABLE 53 PERITONEAL DIALYSIS EQUIPMENT MARKET SHARE BY MANUFACTURER, 2014 (%)</i>	140
CONTINUOUS RENAL REPLACEMENT THERAPIES	140
SLOW CONTINUOUS ULTRAFILTRATION	141
CONTINUOUS VENO-VENOUS HEMOFILTRATION	141
CONTINUOUS VENO-VENOUS HEMODIALYSIS	141
CONTINUOUS VENO-VENOUS HEMODIAFILTRATION	142
THE U.S. MARKET FOR RENAL REPLACEMENT TREATMENT	142

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 54 THE U.S. MARKET FOR ESRD TREATMENT BY TYPE, THROUGH 2021 (\$ MILLIONS)</i>	142
<i>TABLE 55 THE U.S. ESRD POPULATION BY TREATMENT TYPE, 2010-2021 (NUMBER)</i>	143
<i>TABLE 56 THE U.S. ESRD POPULATION BY TREATMENT TYPE, 2010-2021 (PERCENTAGE OF DIALYSIS POPULATION)</i>	143
THE MARKET OF HEMODIALYSIS	143
THE MARKET OF PERITONEAL DIALYSIS	144
DIALYSIS EQUIPMENT COSTS	145
<i>TABLE 57 COSTS FOR COMMON DIALYSIS EQUIPMENT, HD, PD AND CRRT (\$)</i>	145
<i>TABLE 58 MARKET SHARE OF HEMODIALYSIS PRODUCTS, 2014 (%)</i>	146
<i>TABLE 59 COMMERCIAL DIALYSIS SYSTEMS AND MANUFACTURERS (HD, PD, CRRT)</i>	146
THE U.S. MARKET FOR DIALYSIS SYSTEMS AND MAJOR CONSUMABLES	147
DIALYSIS MACHINES	147
<i>TABLE 60 THE U.S. MARKET FOR DIALYSIS SYSTEMS BY TYPE, THROUGH 2021 (\$ MILLIONS)</i>	148
CONSUMABLES	148
<i>TABLE 61 THE U.S. MARKET FOR MAJOR DIALYSIS CONSUMABLES BY TYPE, THROUGH 2021 (\$ MILLIONS)</i>	148
Dialyzers	149
Dialysate	149
DIALYSIS SERVICES	150
<i>TABLE 62 DIALYSIS PATIENTS COUNTS BY UNIT AFFILIATION, 2010-2013 (NO./%)</i>	150
<i>TABLE 63 DIALYSIS CENTER IN THE U.S., 2010-2013 (UNITS/%)</i>	151
MEDICARE'S PAYMENT SYSTEM FOR ESRD TREATMENT	151
NOVEL KIDNEY TREATMENT IN DEVELOPMENT	152
<i>FIGURE 25 SCHEMATIC FOR ARTIFICIAL KIDNEY</i>	152
PORTABLE, CARTRIDGE-BASED HEMODIALYSIS DEVICE	153
WEARABLE PERITONEAL DIALYSIS DEVICE	153
CHAPTER 9 SURGICAL PROCEDURES USED IN RENAL FAILURE TREATMENT	155
VASCULAR ACCESS PROCEDURES	155
AV FISTULA	155
<i>FIGURE 26 FOREARM AV FISTULA</i>	155
AV GRAFT	156
<i>FIGURE 27 AV GRAFT</i>	156
VENOUS CATHETER	157
<i>FIGURE 28 VENOUS CATHETER</i>	157
<i>FIGURE 29 TRENDS IN VASCULAR ACCESS TYPE USE AMONG ESRD PREVALENT PATIENTS, 2003-2014</i>	158
<i>TABLE 64 DISTRIBUTION OF TYPE OF VASCULAR ACCESS IN USE AMONG PREVALENT HEMODIALYSIS PATIENTS IN 2013, FROM CROWNWEB DATA, DECEMBER 2013</i>	162
ACCESS REPLACEMENT AND REPAIR	162
VASCULAR ACCESS MARKET BY TYPE	163
PERITONEAL DIALYSIS CATHETER	163
<i>FIGURE 30 TENCKHOFF CATHETERS</i>	164
PD CATHETERIZATION COSTS	164
KIDNEY TRANSPLANT	164
DECEASED DONORS	165



TOPIC	PAGE NO.
LIVING DONORS	165
THE TRANSPLANT PROCEDURE	165
Donor	165
Recipient	166
Compatibility	166
Post Surgery	167
WAITING LIST FOR KIDNEY TRANSPLANTATION	167
<i>FIGURE 31 PERCENTAGE OF DIALYSIS PATIENTS WAIT-LISTED AND UNADJUSTED KIDNEY TRANSPLANT RATES, 1996-2013 (%)</i>	167
<i>FIGURE 32 PERCENTAGE OF INCIDENT PATIENTS BEING WAIT-LISTED OR RECEIVING A KIDNEY TRANSPLANT WITHIN ONE YEAR OF ESRD INITIATION BY AGE, 1996-2012 (%)</i>	169
<i>TABLE 65 UNADJUSTED KIDNEY TRANSPLANT RATES, ALL DONOR TYPES BY AGE, SEX, RACE AND PRIMARY CAUSE OF ESRD, PER 100 DIALYSIS PATIENT YEARS, 2004-2013</i>	170
<i>FIGURE 33 NUMBER OF KIDNEY TRANSPLANTS, 1996-2013 (THOUSANDS)</i>	170
<i>FIGURE 34 DATA ON AGE, SEX, RACE, AND PRIMARY CAUSE OF DISEASE AMONG KIDNEY TRANSPLANT, 1998-2012</i>	171
SURVIVAL IN POST TRANSPLANTATION	172
<i>FIGURE 35 OUTCOMES IN ADULT KIDNEY TRANSPLANT RECIPIENTS: A) DECEASED DONOR, B) LIVING DONOR</i>	173
ECONOMICS OF KIDNEY TRANSPLANT	173
<i>FIGURE 36 MEDICARE COVERAGE AMONG KIDNEY TRANSPLANT RECIPIENTS (%)</i>	173
THE U.S. MARKET FOR SURGICAL PROCEDURES USED IN TREATING END STAGE RENAL DISEASE	174
<i>TABLE 66 VASCULAR ACCESS USE AT HEMODIALYSIS INITIATION (%)</i>	174
<i>TABLE 67 THE U.S. MARKET FOR SURGICAL PROCEDURES USED IN RENAL FAILURE TREATMENT BY TYPE, THROUGH 2021 (\$ MILLIONS)</i>	175
<i>TABLE 68 ESTIMATED U.S. AVERAGE BILLED CHARGES PER ORGAN TRANSPLANT, 2011 (\$ THOUSANDS)</i>	176
CHAPTER 10 INDUSTRY STRUCTURE	178
PHARMACEUTICALS MANUFACTURERS	178
DIALYSIS EQUIPMENT MAKERS	178
MANUFACTURERS OF DIALYSIS CONSUMABLES	179
THERAPIES	180
DIALYSIS	180
SURGERY	180
NONPROFIT ORGANIZATION PROFILES	181
ESRD NETWORK PROGRAM	181
ORGAN PROCUREMENT AND TRANSPLANTATION NETWORK	182
NATIONAL KIDNEY FOUNDATION	182
COMPANY PROFILES	183
ABBVIE BIOTHERAPEUTICS CORP.	183
ACCELERON PHARMA INC.	183
ACTAVIS PHARMA INC.	184
AKEBIA THERAPEUTICS	184
<i>FIGURE 37 VADADUSTAT CLINICAL DEVELOPMENT</i>	185
AM-PHARMA	185

<b>TOPIC</b>	<b>PAGE NO.</b>
AMAG PHARMACEUTICALS	186
AMERICAN REGENT INC.	186
AMERICAN RENAL ASSOCIATES INC.	187
AMERICAN VASCULAR DIALYSIS ACCESS CENTERS	187
AMGEN	187
ARDELYX	188
<i>FIGURE 38 ARDELYX PIPELINE OVERVIEW</i>	189
ASAHI KASEI KURARAY MEDICAL CO.	190
ASTELLAS PHARMA U.S. INC.	190
ASTRAZENECA PLC	191
AWAK TECHNOLOGIES INC.	192
B.BRAUN MEDICAL INC.	192
BARD ACCESS SYSTEMS INC.	193
BAXTER INTERNATIONAL	193
BAYER PHARMA AG	194
BOEHRINGER INGELHEIM	195
BRISTOL-MYERS SQUIBB	195
BIOCAD	196
CANTEL MEDICAL	196
CENTERS FOR DIALYSIS CARE	197
CHEMOCENTRYX INC.	197
CHONG KUN DANG PHARMACEUTICAL CORP.	198
CONCERT PHARMACEUTICALS INC.	198
DAVITA INC.	199
DIALYSIS CLINIC INC. (DCI)	199
DIVERSIFIED SPECIALTY INSTITUTES (DSI)	200
ELI LILLY AND CO.	200
FIBROGEN INC.	201
<i>FIGURE 39 ROXADUSTAT DEVELOPMENT TIMELINE</i>	201
FRESENIUS MEDICAL CARE (FMC)	202
GENENTECH INC.	203
GENKYOTEX INNOVATION SAS	204
GLAXOSMITHKLINE	204
HOSPIRA INC.	205
INCYTE CORP.	205
JANSSEN PHARMACEUTICALS	206
KERYX BIOPHARMACEUTICALS	206
KIDNEY CENTER INC.	207
KRINGLE PHARMACEUTICAL	207
KYOWA HAKKO KIRIN CO.	207
LIBERTY DIALYSIS	208
MAQUET CARDIOVASCULAR	208
MEDCOMP	209
MEDGENICS INC.	209
MEDICINES CO.	210
MERCK & CO.	210
MYLAN INC.	210

TOPIC	PAGE NO.
NAVILYST MEDICAL	211
NEPHROGENEX INC.	211
NIPRO CORP.	212
NORTHWEST KIDNEY CENTERS	212
NOVARTIS PHARMACEUTICALS	213
NOVO NORDISK A/S	213
NOXXON PHARMA A/G	214
<i>FIGURE 40 NOXXON PIPELINE OVERVIEW</i>	214
NXSTAGE MEDICAL	214
OUTSET MEDICAL INC.	215
PAR PHARMACEUTICAL INC.	216
PANGEN BIOTECH	216
PFIZER PHARMACEUTICAL	217
PROMETHEUS LABORATORIES INC.	217
RENAL RESEARCH INSTITUTE (RRI)	218
RELYPSA, INC	218
RENAL VENTURES MANAGEMENT LLC	219
ROCHE HOLDING A/G (F. HOFFMANN-LA ROCHE LTD.)	219
ROCKWELL MEDICAL TECHNOLOGIES	220
QUANTA FLUID SOLUTION LTD	221
SANOFI-AVENTIS	221
SANDOZ INTERNATIONAL GMBH	222
SATELLITE HEALTHCARE/WELLBOUND	222
SHIRE PHARMACEUTICALS GROUP	222
TAKEDA PHARMACEUTICALS	223
TEVA PHARMACEUTICALS USA	223
THRASOS INNOVATION	224
TORAY INDUSTRIES INC.	224
TRANSVIVO	225
UCB	225
U.S. RENAL CARE INC. (USRC)	226
VASCULAR ACCESS CENTERS	226
VASCULAR PHARMACEUTICALS	227
VIFOR PHARMA LTD.	227
ZS PHARMA INC.	228

**LIST OF TABLES**

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
SUMMARY TABLE THE U.S. MARKET FOR KIDNEY DISEASE TREATMENT, THROUGH 2021 (\$ MILLIONS)	7
TABLE 1 CRITERIA FOR KIDNEY INJURY/DISEASE	13
TABLE 2 STAGES OF CHRONIC KIDNEY DISEASE	18
TABLE 3 COMMON MEDICATIONS THAT CAUSE ACUTE KIDNEY INJURY	31
TABLE 4 RIFLE AND AKIN CRITERIA FOR DIAGNOSIS AND CLASSIFICATION OF AKI	34
TABLE 5 CHARACTERISTICS OF MEDICARE PATIENTS AGED 66 AND ABOVE WITH AT LEAST ONE AKI HOSPITALIZATION: AGE, SEX, RACE, CKD, DM, BY YEAR, 2003-2012	39
TABLE 6 NUMBER OF PATIENTS WITH AKI IN THE UNITED STATES BY AREA, THROUGH 2021	40
TABLE 7 CHARACTERISTICS OF DIALYSIS OPTIONS FOR TREATING AKI	49
TABLE 8 BREAKDOWN OF AVERAGE AKI TREATMENT COSTS BY SUBCATEGORY OF CARE (\$)	51
TABLE 9 U.S. MARKET FOR ACUTE KIDNEY INJURY TREATMENT, THROUGH 2021 (\$ MILLIONS)	52
TABLE 10 STAGES OF CHRONIC KIDNEY DISEASE: A CLINICAL ACTION PLAN	56
TABLE 11 AWARENESS, TREATMENT AND MEASURES OF CONTROL OF RISK FACTORS, 1998-2012 (% OF NHANES PARTICIPANTS)	57
TABLE 12 CLASSIFICATION OF CHRONIC KIDNEY DISEASE BY PATHOLOGY, ETIOLOGY AND PREVALENCE IN PATIENTS WITH ESRD	58
TABLE 13 COMMON MEDICATION ASSOCIATED WITH CHRONIC KIDNEY DISEASE	61
TABLE 14 PATIENTS WITH CKD AND AWARENESS BY STAGE, 2012 (NUMBER AND %)	69
TABLE 15 NUMBER AND PERCENTAGE OF INCIDENT CASES OF HEMODIALYSIS (HD), PERITONEAL DIALYSIS (PD) AND TRANSPLANTATION IN THE U.S. POPULATION BY AGE, SEX, RACE, ETHNICITY AND PRIMARY CAUSE OF ESRD, 2013	72
TABLE 16 PREVALENCE OF CKD IN NHANES POPULATION WITHIN AGE, SEX, RACE/ETHNICITY AND RISK-FACTOR CATEGORIES, 1998-2012 (%)	73
TABLE 17 UNADJUSTED AND ADJUSTED ALL-CAUSE HOSPITALIZATION RATES FOR MEDICARE PATIENTS AGED 66 AND OLDER BY CKD STATUS, 2012	74
TABLE 18 INCIDENCE OF ESRD BY COUNTRY, 2013 (PER MILLION POPULATION)	77
TABLE 19 PREVALENCE OF ESRD BY COUNTRY, 2013 (NO./%)	79
TABLE 20 TOP TEN COUNTRIES HAVING THE HIGHEST % RISE IN ESRD INCIDENCE RATE PLUS THE U.S., 2001 AND 2013	80
TABLE 21 FIVE COUNTRIES HAVING THE LARGEST % DECLINE IN ESRD INCIDENCE RATE, 2001 AND 2013	80
TABLE 22 PERCENTAGE OF INCIDENT ESRD PATIENTS DUE TO DIABETES BY COUNTRY, 2013 (%)	81
TABLE 23 PREVALENCE OF HYPERTENSION AND DYSLIPIDEMIA BY CKD STAGE (%)	85
TABLE 24 THE COMMONLY PRESCRIBED CLASS OF MEDICATION IN CHRONIC KIDNEY DISEASE PATIENTS (%)	86
TABLE 25 RECOMMENDED ANTIHYPERTENSIVE AGENTS FOR PATIENTS WITH CHRONIC KIDNEY DISEASE AND HYPERTENSION	87
TABLE 26 COMMONLY PRESCRIBED ACE INHIBITORS: BRAND NAME, GENERIC NAME AND MANUFACTURER	88
TABLE 27 COMMONLY PRESCRIBED ANGIOTENSIN RECEPTOR BLOCKERS: BRAND NAME, GENERIC NAME AND MANUFACTURER	88
TABLE 28 COMMONLY PRESCRIBED BETA BLOCKERS: BRAND NAME, GENERIC NAME AND MANUFACTURER	89
TABLE 29 COMMONLY PRESCRIBED CALCIUM CHANNEL BLOCKERS: BRAND NAME, GENERIC NAME AND MANUFACTURER	90

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
TABLE 30 LIST OF ANTIHYPERKALEMIA MEDICATION IN DEVELOPMENT: BRAND NAME, GENERIC NAME, MANUFACTURER AND CLINICAL STAGE	93
TABLE 31 COMMONLY PRESCRIBED PHOSPHATE BINDER: BRAND NAME, GENERIC NAME AND MANUFACTURER	94
TABLE 32 COMMONLY PRESCRIBED STATIN: BRAND NAME, GENERIC NAME AND MANUFACTURER	95
TABLE 33 COMMONLY PRESCRIBED BILE ACID SEQUESTRANTS: BRAND NAME, GENERIC NAME AND MANUFACTURER	96
TABLE 34 COMMONLY PRESCRIBED FIBRATES: BRAND NAME, GENERIC NAME AND MANUFACTURER	97
TABLE 35 COMMONLY PRESCRIBED DIURETICS: BRAND NAME, GENERIC NAME AND MANUFACTURER	99
TABLE 36 COMMONLY PRESCRIBED ERYTHROPOIESIS-STIMULATING AGENTS: BRAND NAME, GENERIC NAME AND MANUFACTURER	100
TABLE 37 LIST OF HIF-PH INHIBITORS IN THE DEVELOPMENT: MANUFACTURER AND RESPECTIVE CLINICAL STAGE	103
TABLE 38 COMMONLY PRESCRIBED IRON SUPPLEMENT: BRAND NAME, GENERIC NAME AND MANUFACTURER	105
TABLE 39 COMMONLY PRESCRIBED GLUCOSE MANAGEMENT: BRAND NAME, GENERIC NAME AND MANUFACTURER	106
TABLE 40 LIST OF NOVEL AGENT FOR TREATING DIABETIC NEPHROPATHY: MANUFACTURER AND RESPECTIVE CLINICAL STAGE	108
TABLE 41 COMMONLY PRESCRIBED MEDICATION FOR CHRONIC KIDNEY DISEASE: BRAND NAME, GENERIC NAME AND MANUFACTURER	109
TABLE 42 COMMONLY PRESCRIBED IMMUNOSUPPRESSANT DRUGS: BRAND NAME, GENERIC NAME AND MANUFACTURER	115
TABLE 43 IMMUNOSUPPRESSION MAINTENANCE REGIMEN AT DISCHARGE AND 1 YEAR AFTER TRANSPLANT, 2006	116
TABLE 44 IMMUNOSUPPRESSION DRUG USE, INDUCTION DRUGS, AT DISCHARGE, AT ONE YEAR POSTTRANSPLANT, 2005 AND 2006 (%)	117
TABLE 45 FACTOR LINKED WITH NONCOMPLIANCE IN CHRONIC DISEASE	118
TABLE 46 COSTS OF COMMONLY USED PRESCRIPTION DRUGS FOR TREATING RENAL FAILURE AND ASSOCIATED DISEASES	119
TABLE 47 THE U.S. MARKET FOR PHARMACEUTICALS USED IN CHRONIC KIDNEY DISEASE TREATMENT BY TYPE, THROUGH 2021 (\$ MILLIONS)	121
TABLE 48 COMMON DRUG CLASSES USED BY PART D-ENROLLED DIALYSIS PATIENTS, BY PERCENTAGE OF PATIENTS, DRUG CLASS, 2013 (%)	122
TABLE 49 COMPARISON OF 2008 AND 2012-BASED ESRD MARKET BASKET COST CATEGORIES AND WEIGHTS	123
TABLE 50 MARKET SHARE OF OVERALL DIALYSIS PRODUCTS, 2014 (%)	128
TABLE 51 DIALYSATE PRODUCTS FOR HD, PD AND CRRT	134
TABLE 52 PERITONEAL DIALYSIS SYSTEMS, TYPE AND MANUFACTURER	140
TABLE 53 PERITONEAL DIALYSIS EQUIPMENT MARKET SHARE BY MANUFACTURER, 2014 (%)	140
TABLE 54 THE U.S. MARKET FOR ESRD TREATMENT BY TYPE, THROUGH 2021 (\$ MILLIONS)	142
TABLE 55 THE U.S. ESRD POPULATION BY TREATMENT TYPE, 2010-2021 (NUMBER)	143
TABLE 56 THE U.S. ESRD POPULATION BY TREATMENT TYPE, 2010-2021 (PERCENTAGE OF DIALYSIS POPULATION)	143
TABLE 57 COSTS FOR COMMON DIALYSIS EQUIPMENT, HD, PD AND CRRT (\$)	145
TABLE 58 MARKET SHARE OF HEMODIALYSIS PRODUCTS, 2014 (%)	146
TABLE 59 COMMERCIAL DIALYSIS SYSTEMS AND MANUFACTURERS (HD, PD, CRRT)	146

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
TABLE 60 THE U.S. MARKET FOR DIALYSIS SYSTEMS BY TYPE, THROUGH 2021 (\$ MILLIONS)	148
TABLE 61 THE U.S. MARKET FOR MAJOR DIALYSIS CONSUMABLES BY TYPE, THROUGH 2021 (\$ MILLIONS)	148
TABLE 62 DIALYSIS PATIENTS COUNTS BY UNIT AFFILIATION, 2010-2013 (NO./%)	150
TABLE 63 DIALYSIS CENTER IN THE U.S., 2010-2013 (UNITS/%)	151
TABLE 64 DISTRIBUTION OF TYPE OF VASCULAR ACCESS IN USE AMONG PREVALENT HEMODIALYSIS PATIENTS IN 2013, FROM CROWNWEB DATA, DECEMBER 2013	162
TABLE 65 UNADJUSTED KIDNEY TRANSPLANT RATES, ALL DONOR TYPES BY AGE, SEX, RACE AND PRIMARY CAUSE OF ESRD, PER 100 DIALYSIS PATIENT YEARS, 2004-2013	170
TABLE 66 VASCULAR ACCESS USE AT HEMODIALYSIS INITIATION (%)	174
TABLE 67 THE U.S. MARKET FOR SURGICAL PROCEDURES USED IN RENAL FAILURE TREATMENT BY TYPE, THROUGH 2021 (\$ MILLIONS)	175
TABLE 68 ESTIMATED U.S. AVERAGE BILLED CHARGES PER ORGAN TRANSPLANT, 2011 (\$ THOUSANDS)	176

**LIST OF FIGURES**

<b>FIGURE TITLE</b>	<b>PAGE NO.</b>
SUMMARY FIGURE THE U.S. MARKET FOR KIDNEY DISEASE TREATMENT, 2015-2021 (\$ MILLIONS)	7
FIGURE 1 RENAL STATUS ONE YEAR FOLLOWING DISCHARGE FROM AKI HOSPITALIZATION AMONG MEDICARE PATIENTS AGED 66+, 2010-2011 (% OF PATIENTS WITHOUT CKD BEFORE AKI)	19
FIGURE 2 POTENTIAL OUTCOME OF ACUTE KIDNEY INJURY	20
FIGURE 3 CARDIOVASCULAR DISEASE IN PATIENTS WITH OR WITHOUT CKD, 2012 (%)	22
FIGURE 4 TRENDS OF KIDNEY DISEASE INCIDENT RATE IN THE U.S.,1980-2005	26
FIGURE 5 CLASSIFICATION OF ACUTE KIDNEY INJURY	30
FIGURE 6 TREATMENT FLOWCHART FOR ACUTE KIDNEY INJURY	35
FIGURE 7 NUMBER OF HOSPITALIZATIONS WITH ACUTE KIDNEY INJURY, 1979-2002	37
FIGURE 8 SCHEMATIC OF CONTINUOUS RENAL REPLACEMENT THERAPY	46
FIGURE 9 SCHEMATIC OF DIFFERENT TYPES OF CRRT	48
FIGURE 10 SCHEMATIC REPRESENTATION OF THE MECHANISMS UNDERLYING ANEMIA OF CKD	63
FIGURE 11 RECOGNIZED MOLECULAR MECHANISMS INVOLVED IN PATHOGENESIS OF DIABETIC KIDNEY DISEASE	65
FIGURE 12 MECHANISMS OF PHOSPHATE HOMEOSTASIS	67
FIGURE 13 CKD PATIENTS AWARE OF THEIR KIDNEY DISEASE, 2001-2012	69
FIGURE 14 PREVALENCE OF CKD BY STAGE AMONG NHANES PARTICIPANTS, 1988-2012	70
FIGURE 15 TRENDS IN NUMBER OF PREVALENT ESRD CASES IN THE U.S. POPULATION BY AGE GROUP, 1996-2013 (THOUSANDS)	70
FIGURE 16 ADJUSTED ALL-CAUSE HOSPITALIZATION RATES FOR MEDICARE PATIENTS AGED 66 AND OLDER BY CKD STATUS AND STAGE, 2012 (NO. OF ADMISSIONS)	74
FIGURE 17 ADJUSTED ALL-CAUSE HOSPITALIZATION RATES IN MEDICARE PATIENTS AGED 66 AND OLDER, BY RACE, CKD STATUS AND STAGE, 2012	75
FIGURE 18 UNADJUSTED AND ADJUSTED ALL-CAUSE MORTALITY RATE FOR MEDICARE PATIENTS	76
FIGURE 19 IMMUNOSUPPRESSION USE IN PEDIATRIC KIDNEY TRANSPLANT RECIPIENTS	115
FIGURE 20 MECHANISMS OF SOLUTE REMOVAL IN DIALYSIS	126
FIGURE 21 TRENDS IN THE NUMBER OF INCIDENT CASES OF ESRD IN THE U.S. POPULATION BY MODALITY, 1980-2012 (THOUSANDS)	127
FIGURE 22 SCHEMATIC OF THE HEMODIALYSIS MEMBRANE	129
FIGURE 23 SCHEMATIC OF TYPICAL HEMODIALYSIS SYSTEM	131
FIGURE 24 CONTINUOUS AMBULATORY PERITONEAL DIALYSIS	138
FIGURE 25 SCHEMATIC FOR ARTIFICIAL KIDNEY	152
FIGURE 26 FOREARM AV FISTULA	155
FIGURE 27 AV GRAFT	156
FIGURE 28 VENOUS CATHETER	157
FIGURE 29 TRENDS IN VASCULAR ACCESS TYPE USE AMONG ESRD PREVALENT PATIENTS, 2003-2014	158
FIGURE 30 TENCKHOFF CATHETERS	164
FIGURE 31 PERCENTAGE OF DIALYSIS PATIENTS WAIT-LISTED AND UNADJUSTED KIDNEY TRANSPLANT RATES, 1996-2013 (%)	167

---

<b>FIGURE TITLE</b>	<b>PAGE NO.</b>
FIGURE 32 PERCENTAGE OF INCIDENT PATIENTS BEING WAIT-LISTED OR RECEIVING A KIDNEY TRANSPLANT WITHIN ONE YEAR OF ESRD INITIATION BY AGE, 1996-2012 (%)	169
FIGURE 33 NUMBER OF KIDNEY TRANSPLANTS, 1996-2013 (THOUSANDS)	170
FIGURE 34 DATA ON AGE, SEX, RACE, AND PRIMARY CAUSE OF DISEASE AMONG KIDNEY TRANSPLANT, 1998-2012	171
FIGURE 35 OUTCOMES IN ADULT KIDNEY TRANSPLANT RECIPIENTS: A) DECEASED DONOR, B) LIVING DONOR	173
FIGURE 36 MEDICARE COVERAGE AMONG KIDNEY TRANSPLANT RECIPIENTS (%)	173
FIGURE 37 VADADUSTAT CLINICAL DEVELOPMENT	185
FIGURE 38 ARDELYX PIPELINE OVERVIEW	189
FIGURE 39 ROXADUSTAT DEVELOPMENT TIMELINE	201
FIGURE 40 NOXXON PIPELINE OVERVIEW	214